A relationship cardiologists have long known about, finally given a rulebook

Heart disease and kidney disease have been recognized as intertwined for decades, each one capable of accelerating the other in a feedback loop that leaves patients worse off than either condition would cause alone. Despite that well-established relationship, cardiology has never had a dedicated, formal guideline addressing exactly how to screen for and manage that overlap, until now. The European Society of Cardiology, working in partnership with the European Renal Association, published its first-ever guidelines specifically covering cardiovascular disease and chronic kidney disease together, released in the European Heart Journal and presented at ESC Congress 2026 on August 29.

The core recommendation is straightforward enough to summarize in one sentence, even if implementing it consistently across cardiology practices will take real work: every patient diagnosed with cardiovascular disease should now be screened for chronic kidney disease as a routine part of their care, not as an afterthought triggered only by separate kidney-specific symptoms.

Why this overlap deserved its own guideline

The scale of the problem driving this decision is substantial. An estimated 100 million people across Europe live with chronic kidney disease, and virtually all of them face elevated risk for a wide range of cardiovascular conditions as a direct consequence. Task Force Chair Associate Professor Kevin Damman, from University Medical Center Groningen in the Netherlands, described the stakes in stark terms: "The disability and lifetime lost to each disease are profound, but CKD can accelerate CVD and vice versa, resulting in cardiovascular events and the need for dialysis much earlier in life."

That bidirectional acceleration is the specific clinical problem this guideline targets. A patient with undiagnosed kidney impairment who develops heart disease faces a meaningfully different risk trajectory than a patient with healthy kidneys, yet without routine screening, that kidney impairment often goes undetected until it's already influencing how aggressively the underlying heart condition needs to be managed, or until it's progressed far enough to require dialysis sooner than it otherwise would have.

What screening actually looks like under the new guidance

The guideline defines chronic kidney disease as abnormalities of kidney structure or function persisting for at least three months with genuine health implications, and it specifies exactly how that should be assessed. Screening should include two tests: an estimated glomerular filtration rate, calculated from a blood creatinine test, alongside a urine albumin-to-creatinine ratio, a separate test measuring how much protein is leaking into urine. Neither test is exotic or expensive; both are already standard tools in nephrology, and the guideline's real innovation is mandating their routine use specifically at the point of cardiovascular disease diagnosis, rather than leaving that decision to individual clinician judgment or waiting for kidney-specific symptoms to appear.

To help translate that recommendation into a memorable clinical routine, the task force introduced a five-step framework they're calling STAMP on CKD: Screen, Triage, Address CKD Risk, Modify CVD Management, and Plan Health Services. That kind of acronym-based framework is a deliberate communication choice, aimed at making a genuinely complex, multi-step clinical workflow easier for busy cardiologists to actually remember and apply consistently across a high patient volume, rather than treating kidney screening as a specialized add-on task requiring a separate referral before any action gets taken.

Moving from separate specialties to coordinated care

Perhaps the more significant shift buried inside this guideline isn't the screening protocol itself, but what it implies about how these two conditions should be managed once identified together. Historically, cardiology and nephrology have often operated as genuinely separate specialties, each managing its own organ system with its own risk calculators, its own preferred medications, and its own follow-up schedules, even when treating the same patient. The new guideline explicitly pushes toward a more integrated model, recommending risk stratification that treats cardiovascular and kidney risk as a single combined assessment using validated tools that incorporate kidney function directly into cardiovascular risk calculations, rather than scoring the two separately and reconciling the results after the fact.

That integration extends to treatment recommendations as well. The guidance specifically highlights therapies already shown to reduce both cardiovascular and kidney complications simultaneously, including SGLT2 inhibitors, medications originally developed for diabetes that have since demonstrated genuine protective effects on both the heart and kidneys, alongside RAS inhibitors and statin therapy. Prescribing decisions built around a single combined risk profile, rather than a cardiology-only or nephrology-only lens, is a meaningfully different way of practicing than treating each organ system's risk in isolation.

Why earlier detection matters more than it might sound

The practical value of catching chronic kidney disease earlier, specifically at the moment a patient is first diagnosed with cardiovascular disease, comes down to a fairly direct logic: kidney function decline is often gradual and can be asymptomatic well into its progression, meaning patients frequently don't know their kidneys are already compromised until the damage has advanced considerably. A cardiovascular disease diagnosis creates a natural, already-scheduled clinical touchpoint where a simple blood and urine test can catch that decline years earlier than it might otherwise surface, at a stage when interventions like SGLT2 inhibitors have more capacity to slow further progression.

That logic mirrors a broader pattern showing up across cardiology guidance this year: catching risk earlier, and treating it more comprehensively, even in patient populations or organ systems that weren't traditionally the primary focus of a given specialty. It's a similar philosophy underlying recent trial results on statin therapy specifically in adults over 70, also presented at this year's ESC Congress, where researchers found meaningful cardiovascular benefit from a preventive intervention in a population many clinicians had previously assumed was too old, or too far along, to benefit meaningfully from earlier treatment.

What this means for patients and clinicians going forward

For patients, the practical change is straightforward: anyone receiving a cardiovascular disease diagnosis going forward should expect two additional, simple, non-invasive tests, a blood creatinine measurement and a urine albumin-to-creatinine check, as part of that diagnostic workup, rather than these tests being reserved for patients who separately raise kidney-related concerns. For clinicians, the shift is somewhat larger: the guideline asks cardiologists to think about kidney function as a routine, integrated part of cardiovascular risk assessment rather than a separate specialty concern to be handed off elsewhere once flagged.

Guidelines of this kind typically take time to fully embed into everyday clinical practice, since updating institutional protocols, electronic health record prompts, and individual clinician habits doesn't happen overnight simply because a new recommendation has been published. But the existence of a formal, jointly developed guideline from two major European medical societies gives hospitals and health systems a concrete, citable standard to build implementation around, a meaningfully stronger lever for actually changing routine practice than informal awareness of the cardiovascular-kidney link that clinicians have understood, in a general sense, for years without a standardized protocol translating that understanding into consistent action.